Antipsychotic drugs relieve symptoms of schizophrenia as well as manic-depressive illness. The first generation drugs, however, were ineffective in many patients and failed to alleviate features such as emotional withdrawal reflecting the """"""""negative"""""""" symptoms of schizophrenia. A new generation, """"""""atypical"""""""" antipsychotic drugs (AAPDs), help non-responders, ameliorate negative symptoms, have fewer side-effects and so have emerged as some of the most widely used of all drugs. However, their use has been hampered by adverse metabolic side effects including severe weight gain elicited by some of those agents, sometimes doubling patient weights and with no clear cut explanation. We have found that the drugs that cause weight gain potently and selectively activate the enzyme AMP-kinase (AMPK) in the hypothalamic area of the brain in discrete nuclei which regulate eating behavior. This activation occurs secondary to the drugs'blocking the histamine H1 receptor for histamine, which, besides its roles in allergy, is a neurotransmitter in the feeding centers of the hypothalamus. Our preliminary studies indicate that inositol polyphosphate multikinase (IPMK), which utilizes one of the downstream molecules (inositol 1,4,5-triphosphate) produced upon histamine H1 receptor activation, is required for AMPK regulation. Also, the expression level of IPMK in the hypothalamus is modulated by energy balance. These intriguing observations led us to hypothesize that IPMK is the main mediator between histamine H1 receptor and AMPK regulation in the hypothalamus. Hence, in this proposal we will investigate the novel role of IPMK on AMPK modulation and energy homeostasis. We will characterize the molecular mechanism by which IPMK regulates AMPK modulation in the hypothalamus (Aim1). Moreover, we will investigate the posttranslational modification of IPMK, which can lead to a change of eating behavior via AMPK modulation (Aim 2). Finally, the contribution of IPMK in energy homeostasis and AAPDs-mediated weight gain in animal model will be investigated utilizing ipmkloxP/loxP mice (Aim3). Together, these studies will unveil not only the molecular basis of AAPD-mediated weight gain but also a novel signaling mechanism by which appetite is regulated in the hypothalamus. Accordingly, more efficient and effective strategies could be developed to manage the patients experiencing APPD-related metabolic side effects.

Public Health Relevance

The use of second generation antipsychotic drugs greatly improved the treatment of psychosis such as schizophrenia but its unexpected metabolic side effects such as weight gain hampered their use. These side effects have a significant effect on their health implication as well as patient's low self-esteem and, consequently on low compliance. Hence, it is upmost importance to identify the molecular mechanism of how AAPDs lead to an excessive weight gain.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK084336-04
Application #
8512717
Study Section
Special Emphasis Panel (ZRG1-RPHB-L (52))
Program Officer
Pawlyk, Aaron
Project Start
2010-08-01
Project End
2015-07-31
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
4
Fiscal Year
2013
Total Cost
$288,554
Indirect Cost
$108,208
Name
University of Pennsylvania
Department
Psychiatry
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Carlson, G C; Lin, R E; Chen, Y et al. (2016) Dexras1 a unique ras-GTPase interacts with NMDA receptor activity and provides a novel dissociation between anxiety, working memory and sensory gating. Neuroscience 322:408-15
Chen, Yong; Bang, Sookhee; McMullen, Mary F et al. (2016) Neuronal Activity-Induced Sterol Regulatory Element Binding Protein-1 (SREBP1) is Disrupted in Dysbindin-Null Mice-Potential Link to Cognitive Impairment in Schizophrenia. Mol Neurobiol :
White, Rachel S; Bhattacharya, Anup K; Chen, Yong et al. (2016) Lysosomal iron modulates NMDA receptor-mediated excitation via small GTPase, Dexras1. Mol Brain 9:38
Chen, Yong; Mathias, Lauren; Falero-Perez, Juliana M et al. (2015) PKA-mediated phosphorylation of Dexras1 suppresses iron trafficking by inhibiting S-nitrosylation. FEBS Lett 589:3212-9
Chen, Yong; Bang, Sookhee; Park, Soohyun et al. (2015) Acyl-CoA-binding domain containing 3 modulates NAD+ metabolism through activating poly(ADP-ribose) polymerase 1. Biochem J 469:189-98
Kim, Sangwon F (2014) The nitric oxide-mediated regulation of prostaglandin signaling in medicine. Vitam Horm 96:211-45
Bang, Sookhee; Chen, Yong; Ahima, Rexford S et al. (2014) Convergence of IPMK and LKB1-AMPK signaling pathways on metformin action. Mol Endocrinol 28:1186-93
Arnold, Steven E; Lucki, Irwin; Brookshire, Bethany R et al. (2014) High fat diet produces brain insulin resistance, synaptodendritic abnormalities and altered behavior in mice. Neurobiol Dis 67:79-87
Chen, Yong; Khan, Reas S; Cwanger, Alyssa et al. (2013) Dexras1, a small GTPase, is required for glutamate-NMDA neurotoxicity. J Neurosci 33:3582-7
Salvemini, Daniela; Kim, Sangwon F; Mollace, Vincenzo (2013) Reciprocal regulation of the nitric oxide and cyclooxygenase pathway in pathophysiology: relevance and clinical implications. Am J Physiol Regul Integr Comp Physiol 304:R473-87

Showing the most recent 10 out of 18 publications